Altamira Therapeutics files provisional patent application for OligoPhore

Altamira Therapeutics has filed a provisional patent application with the United States Patent Office which covers nanoparticles comprising the Company’s OligoPhore platform and siRNA targeting the p65 protein, a component of the NF-B transcription factor. The provisional patent application describes novel nanoparticle compositions based on OligoPhore, Altamira’s peptide-based oligonucleotide delivery platform, or derivatives thereof in combination with siRNA sequences designed to silence p65. Activation of p65 has been observed in multiple types of cancer as well as in many inflammatory diseases and its function has been implicated in the pathogenesis of these diseases. For instance, p65 is a well-known key checkpoint in rheumatoid arthritis inflammation, and thought to regulate cell proliferation, cell death, and stimulate metastasis in cancer. The new filing is intended to extend Altamira’s intellectual property related to its AM-411 development program for RA treatment, among others.